Allergy, Asthma and Immunology

July 25, 2016

Immunotherapy in allergic rhinitis and lower airway outcomes

Accepted Article (Accepted, unedited articles published online and citable. The final edited and typeset version of record will appear in future.)

Victoria Cardona,

Olga Luengo

and

Moises Labrador

Abstract

Allergic rhinitis and asthma constitute two clinical expressions of a single condition, respiratory allergy. Allergen immunotherapy (AIT) is a form of treatment specifically aimed at modifying the response to sensitizing allergens. The inherent potential benefit of AIT is the simultaneous treatment of all clinical expressions of respiratory allergy. Current data support the effectiveness of subcutaneous and sublingual immunotherapy in rhinitis. Studies also provide proof for a beneficial effect in allergic asthma. Even more, substantial evidence points to the preventive effect on the progression from rhinitis to asthma.

Abstract

Background

Chronic respiratory diseases are a significant cause of morbidity and mortality worldwide. We sought to evaluate the impact of asthma, chronic bronchitis and allergic rhinitis on all-cause hospitalizations and limitations in daily activities in adults.

July 22, 2016

Drug allergy passport and other documentation for patients with drug hypersensitivity – An ENDA/EAACI Drug Allergy Interest Group Position Paper

Allergy

Accepted Article (Accepted, unedited articles published online and citable. The final edited and typeset version of record will appear in future)

K. Brockow^1,*,

W. Aberer²,

M. Atanaskovic-Markovic³,

S. Bavbek⁴,

A. Bircher⁵,

B. Bilo⁶,

M. Blanca⁷,

P. Bonadonna⁸,

G. Burbach⁹,

G. Calogiuri¹⁰,

C. Caruso¹¹,

G. Celik¹²,

J. Cernadas¹³,

A Chiriac¹⁴,

P. Demoly¹⁴,

J.N.G. Oude Elberink¹⁵,

J. Fernandez¹⁶,

E. Gomes¹⁷,

L. H. Garvey¹⁸,

J. Gooi¹⁹,

M. Gotua²⁰,

M. Grosber¹,

P. Kauppi²¹,

V. Kvedariene²²,

J. J. Laguna²³,

J. Makoswska²⁴,

H. Mosbech¹⁸,

A. Nakonechna²⁵,

N. G. Papadopolous²⁶,

J. Ring¹,

A. Romano^11,27,

H. Rockmann²⁸,

R. Sargur²⁹,

L. Sedlackova³⁰,

S. Sigurdardottir³¹,

B. Schnyder³²,

T. Storaas³³,

M. Torres⁷,

M. Zidarn³⁴ and

I. Terreehorst³⁵

Summary

The strongest and best-documented risk factor for drug hypersensitivity (DH) is the history of a previous reaction. Accidental exposures to drugs to may lead to severe or even fatal reactions in sensitised patients. Preventable prescription errors are common. They are often due to inadequate medical history or poor risk assessment of recurrence of drug reaction. Proper documentation is essential information for the doctor to make sound therapeutic decision. The European Network on Drug Allergy and Drug Allergy Interest Group of the European Academy of Allergy and Clinical Immunology have formed a task force and developed a drug allergy passport as well as general guidelines of drug allergy documentation.

ABSTRACT

Background: More people are seeking health information online than ever before and pharmaceutical companies are increasingly marketing their drugs through social media.

Objective: The aim was to examine two major concerns related to online direct-to-consumer pharmaceutical advertising: (1) how disclosing an affiliation with a pharmaceutical company affects how people respond to drug information produced by both health organizations and online commenters, and (2) how knowledge that health organizations control the display of user-generated comments affects consumer health knowledge and behavior.

ABSTRACT

Background: Social media promotion is increasingly adopted by organizers of industry and academic events; however, the success of social media strategies is rarely questioned or the real impact scientifically analyzed.

Objective: We propose a framework that defines and analyses the impact, outreach, and effectiveness of social media for event promotion and research dissemination to participants of a scientific event as well as to the virtual audience through the Web.

Abstract

Background

Bilastine, a novel non-sedating second-generation H1 antihistamine, has been approved in most European countries since 2010. This study aimed to evaluate the superiority of bilastine over placebo in Japanese patients with perennial allergic rhinitis (PAR).

Allergy, Asthma and Immunology

Menu

July 25, 2016

Immunotherapy in allergic rhinitis and lower airway outcomes

July 24, 2016

The impact of asthma, chronic bronchitis and allergic rhinitis on all-cause hospitalizations and limitations in daily activities: a population-based observational study

July 23, 2016

Rhinitis- a Primer for Specialists - Prof. Mark Dykewicz

Rhinitis- a Primer for Specialists (Prof. Mark Dykewicz)

July 22, 2016

Drug allergy passport and other documentation for patients with drug hypersensitivity – An ENDA/EAACI Drug Allergy Interest Group Position Paper

Allergy

Summary

July 20, 2016

How Affiliation Disclosure and Control Over User-Generated Comments Affects Consumer Health Knowledge and Behavior

Journal of Medical Internet Research Published on 19.07.16 in Vol 18, No 7 (2016): July

Original Paper

Measuring the Role and Effectiveness of Online and Social Media in Increasing the Outreach of a Scientific Conference

Journal of Medical Internet Research Published on 19.07.16 in Vol 18, No 7 (2016): July

Original Paper

Efficacy and safety of bilastine in Japanese patients with perennial allergic rhinitis: A multicenter, randomized, double-blind, placebo-controlled, parallel-group phase III study

Article Info

Abstract

July 16, 2016

Dr. Sergio Rosenzweig discusses how to diagnose a patient who has primary immunodefiency.

Dr. Leonard Bielory discusses management of allergies of the eye

ACAAICOLA

Get new posts by email: